US Stem Cell Inc (USRM)

[NoMoDo]

U.S. Stem Cell, Inc. Reports Continued Positive Results for Q1 2017
Posted by U.S. Stem Cell, Inc

Sunrise, FL – May 3, 2017 – U.S. STEM CELL, Inc., a Florida corporation, a leader in the regenerative medicine, cellular therapy industry providing physician based stem cell therapies to human and animal patients as well as a developer of novel autologous cell therapies, is pleased to highlight the following results from operations for the quarter ending March 31, 2017:

Revenue up by 62% from $710,000 in Q1 2016 to $1.15M in Q1 2017
Gross profit up by 45.6% from $556,000 in Q1 2016 to $810,000 in Q1 2017
Cash Flow is positive Q1 2017 at $268,000 compared to Q1 2016 at ($62,000)
All debt-to-equity convertible notes have been either fully paid or converted as of March 31, 2017.

“We are very pleased with the 2017 improvements in operations and balance sheet performance,” said Mike Tomás, President & CEO of U.S. Stem Cell, Inc. “We are progressing with our principal strategic business initiatives which include growing top line revenues and pursuing new business opportunities for exponential growth.”

U.S. Stem Cell, Inc. continues to make a positive impact on the lives of patients treated using its procedures. This year we hope to continue our accomplishments and value for both patients and shareholders.